408 related articles for article (PubMed ID: 31748977)
21. Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1.
Kumamoto T; Yamazaki F; Nakano Y; Tamura C; Tashiro S; Hattori H; Nakagawara A; Tsunematsu Y
Int J Clin Oncol; 2021 Dec; 26(12):2161-2178. PubMed ID: 34633580
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of germline mutations in the TP53 gene in patients with early-onset breast cancer in the Mexican population.
Gallardo-Alvarado LN; Tusié-Luna MT; Tussié-Luna MI; Díaz-Chávez J; Segura YX; Bargallo-Rocha E; Villarreal C; Herrera-Montalvo LA; Herrera-Medina EM; Cantu-de Leon DF
BMC Cancer; 2019 Feb; 19(1):118. PubMed ID: 30709381
[TBL] [Abstract][Full Text] [Related]
23. Identification and Management of
Pal T; Brzosowicz J; Valladares A; Wiesner GL; Laronga C
South Med J; 2017 Oct; 110(10):643-648. PubMed ID: 28973705
[TBL] [Abstract][Full Text] [Related]
24. Radiation therapy and secondary malignancy in Li-Fraumeni syndrome: A hereditary cancer registry study.
Hendrickson PG; Luo Y; Kohlmann W; Schiffman J; Maese L; Bishop AJ; Lloyd S; Kokeny KE; Hitchcock YJ; Poppe MM; Gaffney DK; Tao R
Cancer Med; 2020 Nov; 9(21):7954-7963. PubMed ID: 32931654
[TBL] [Abstract][Full Text] [Related]
25. TP53 p.R337H is a conditional cancer-predisposing mutation: further evidence from a homozygous patient.
Giacomazzi J; Selistre S; Duarte J; Ribeiro JP; Vieira PJ; de Souza Macedo G; Rossi C; Czepielewski M; Netto CB; Hainaut P; Ashton-Prolla P
BMC Cancer; 2013 Apr; 13():187. PubMed ID: 23570263
[TBL] [Abstract][Full Text] [Related]
26. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
[TBL] [Abstract][Full Text] [Related]
27. The profile and contribution of rare germline copy number variants to cancer risk in Li-Fraumeni patients negative for TP53 mutations.
Silva AG; Krepischi AC; Pearson PL; Hainaut P; Rosenberg C; Achatz MI
Orphanet J Rare Dis; 2014 Apr; 9():63. PubMed ID: 24775443
[TBL] [Abstract][Full Text] [Related]
28. Identification of the
Sandoval RL; Masotti C; de Macedo MP; Ribeiro MFSA; Leite ACR; Meireles SI; Bovolin RM; Santini FC; Munhoz RR; Jardim DLF; Katz A; Camargo AA; Fernandes GDS; Achatz MI
JCO Glob Oncol; 2021 Jul; 7():1141-1150. PubMed ID: 34270331
[TBL] [Abstract][Full Text] [Related]
29. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.
Mai PL; Best AF; Peters JA; DeCastro RM; Khincha PP; Loud JT; Bremer RC; Rosenberg PS; Savage SA
Cancer; 2016 Dec; 122(23):3673-3681. PubMed ID: 27496084
[TBL] [Abstract][Full Text] [Related]
30. TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family.
Kappel S; Janschek E; Wolf B; Rudas M; Teleky B; Jakesz R; Kandioler D
Breast Cancer Res Treat; 2015 Jun; 151(3):671-8. PubMed ID: 25981898
[TBL] [Abstract][Full Text] [Related]
31. MIR605 rs2043556 is associated with the occurrence of multiple primary tumors in TP53 p.(Arg337His) mutation carriers.
Bandeira IC; Vieira IA; Andreis TF; Brussa Reis L; Macedo GS; Vianna FSL; Santos-Silva P; Palmero EI; Galvão HCR; Ramos CRN; Santiago KM; Achatz MI; da Costa AABA; Ashton-Prolla P
Cancer Genet; 2020 Jan; 240():54-58. PubMed ID: 31778928
[TBL] [Abstract][Full Text] [Related]
32. Rare germline variant (rs78378222) in the TP53 3' UTR: Evidence for a new mechanism of cancer predisposition in Li-Fraumeni syndrome.
Macedo GS; Araujo Vieira I; Brandalize AP; Giacomazzi J; Inez Palmero E; Volc S; Rodrigues Paixão-Côrtes V; Caleffi M; Silva Alves M; Achatz MI; Hainaut P; Ashton-Prolla P
Cancer Genet; 2016 Mar; 209(3):97-106. PubMed ID: 26823150
[TBL] [Abstract][Full Text] [Related]
33. Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil.
Palmero EI; Schüler-Faccini L; Caleffi M; Achatz MI; Olivier M; Martel-Planche G; Marcel V; Aguiar E; Giacomazzi J; Ewald IP; Giugliani R; Hainaut P; Ashton-Prolla P
Cancer Lett; 2008 Mar; 261(1):21-5. PubMed ID: 18248785
[TBL] [Abstract][Full Text] [Related]
34. Association between Predicted Effects of
Liu Y; Axell O; van Leeuwen T; Konrat R; Kharaziha P; Larsson C; Wright APH; Bajalica-Lagercrantz S
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34198491
[TBL] [Abstract][Full Text] [Related]
35. Rectal leiomyosarcoma as the initial phenotypic manifestation of Li-Fraumeni-like syndrome: a case report and review of the literature.
Severino NP; Waisberg J; Fragoso MCBV; de Lima LGCA; Balsamo F; Henriques AC; Bianco B; de Sousa Gehrke F
J Med Case Rep; 2022 Dec; 16(1):468. PubMed ID: 36529791
[TBL] [Abstract][Full Text] [Related]
36. TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort.
Bakhuizen JJ; Hogervorst FB; Velthuizen ME; Ruijs MW; van Engelen K; van Os TA; Gille JJ; Collée M; van den Ouweland AM; van Asperen CJ; Kets CM; Mensenkamp AR; Leter EM; Blok MJ; de Jong MM; Ausems MG
Fam Cancer; 2019 Apr; 18(2):273-280. PubMed ID: 30607672
[TBL] [Abstract][Full Text] [Related]
37. New surveillance guidelines for Li-Fraumeni and hereditary TP53 related cancer syndrome: implications for germline TP53 testing in breast cancer.
Evans DG; Woodward ER
Fam Cancer; 2021 Jan; 20(1):1-7. PubMed ID: 32984917
[No Abstract] [Full Text] [Related]
38. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
[TBL] [Abstract][Full Text] [Related]
39. p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriers.
Macedo GS; Vieira IA; Vianna FSL; Alemar B; Giacomazzi J; Brandalize APC; Caleffi M; Volc SM; de Campos Reis Galvão H; Palmero EI; Achatz MI; Ashton-Prolla P
Fam Cancer; 2018 Apr; 17(2):269-274. PubMed ID: 28756477
[TBL] [Abstract][Full Text] [Related]
40. The first two confirmed sub-Saharan African families with germline TP53 mutations causing Li-Fraumeni syndrome.
Macaulay S; Goodyear QC; Kruger M; Chen W; Essop F; Krause A
Fam Cancer; 2018 Oct; 17(4):607-613. PubMed ID: 29392648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
